Pediatrix MedicalNYSE: MD

OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Announces Preliminary Approval of Settlement in MedNax Services, Inc., Customer Data Security Breach Litigation.

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock?

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group To Present at Upcoming Investor Conferences.

Pediatrix Medical Group, Inc. (MD) reported earnings 30 days ago. What's next for the stock?

Pediatrix's (MD) Q4 results were hit by an increase in overall cost level resulting from higher same-unit clinical compensation costs. Yet, an impressive 2024 adjusted EBITDA guidance is likely to provide relief to investors.

Although the revenue and EPS for Pediatrix Medical Group (MD) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Pediatrix Medical's (MD) Q4 results are likely to be hurt by an increase in practice salaries and benefits expense as well as softer patient volumes, partly offset by same-unit pricing growth.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2023 Fourth Quarter Conference Call/Webcast Scheduled for Tuesday, February 20, 2024.

Pediatrix's (MD) third-quarter results suffer from the decline in same-unit revenues attributable to patient volume. Management currently expects 2023 adjusted EBITDA to be within $200-$210 million.